Exhibit 10.1
AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT
AMENDMENT NO. 2 ("Amendment No. 2"), dated as of July 22, 2004 to
Employment Agreement dated as of September 23, 2003, as amended April 29, 2004
(the "Picker Employment Agreement") by and between Callisto Pharmaceuticals,
Inc., a Delaware corporation (the "Company"), and ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, Ph.D., an
individual (the "Executive").
WHEREAS, the parties desire to amend the Picker Employment Agreement to
change the salary of the Executive and to set forth incentive compensation for
the twelve-month period beginning on the date of this Amendment No. 2;
NOW, THEREFORE, in consideration of the covenants and agreements set
forth herein and for other good and valuable consideration, the receipt and
sufficiency of which are hereby mutually acknowledged, the parties hereto
covenant and agree as follows:
1. Amendment to Picker Employment Agreement. The Picker Employment
Agreement is hereby amended as follows:
1.1 Section 1.4 is hereby amended by replacing $175,000 with
$200,000.
1.2 Section 1.5 is hereby deleted and replaced with the following:
1.5 Incentive Compensation. Executive shall be eligible to earn
a cash bonus of up to $92,500 for the twelve-month period
beginning on the date of this Amendment No. 2. Executive's
bonus, if any, shall be subject to all applicable tax and
payroll withholdings. For the twelve-month period beginning on
the date of this Amendment No. 2, Executive shall earn:
(a) $15,000 of his cash bonus upon the successful in-license by
the Company of Annamycin during August 2004.
(b) $7,500 of his cash bonus upon the successful renegotiation
of the AnorMED License Agreement to shift the application milestone
payment to launch (for no consideration).
(c) $10,000 of his cash bonus upon the success of WP760 in
animal studies and the filing of an IND in the fourth quarter of
2005 (the twelve-month period beginning on the date of this
Amendment No. 2 shall be extended until December 31, 2005 only for
this milestone).
(d) $5,000 of his cash bonus upon the reactivation of the
Annamycin IND and the initiation of a Phase IIb clinical study in
the first quarter of 2005.
(e) $25,000 of his cash bonus upon the dosing of the first
patient in a Phase IIb clinical study for Atiprimod by May 15, 2005.
(f) $30,000 of his cash bonus upon the successful in-license of
a 3rd clinical candidate which is ready to enter into a Phase IIb
clinical study (must have complete initial Phase II clinical data).
2. Ratification. The Picker Employment Agreement is ratified and
confirmed and shall continue in full force and effect as amended hereby.
3. Headings and Captions. The headings and captions of the various
subdivisions of this Amendment No. 2 are for convenience of reference only and
shall in no way modify or affect the meaning or construction of any of the terms
or provisions hereof.
4. Counterparts. This Amendment No. 2 may be executed in two or more
counterparts, and by different parties hereto on separate counterparts, each of
which shall be deemed an original, but all of which together shall constitute
one and the same instrument.
2
IN WITNESS WHEREOF, the parties hereto have executed this Amendment No.
2 or caused this Amendment No. 2 to be executed by their duly authorized
representatives as of the date first written above.
CALLISTO PHARMACEUTICALS, INC.
By: /s/ ▇▇▇▇ ▇. ▇▇▇▇▇
-----------------
Name: ▇▇▇▇ ▇. ▇▇▇▇▇, Ph.D.
Title: Chief Executive Officer
/s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
--------------------
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, Ph.D.